Go To Global Site
Welcome to UCB in the United States

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Jan

12

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Nov

30

World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

Nov

17

UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Nov

05

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Oct

31

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

Oct

29

UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology